Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Study sponsor: Can-Fite BioPharma
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-02Estimated
Enrollment · participants471Estimated
Source updated2025-04-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.